These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 20707884)

  • 21. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.
    You JHS; Ming WK; Lee CF; Tsang OT; Chan PK
    Vaccine; 2018 Jul; 36(31):4610-4620. PubMed ID: 29958739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium.
    Annemans L; Bresse X; Gobbo C; Papageorgiou M
    J Med Econ; 2010; 13(3):537-51. PubMed ID: 20707768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Hornberger J; Robertus K
    Ann Intern Med; 2006 Sep; 145(5):317-25. PubMed ID: 16954357
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
    Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
    Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.
    Damm O; Ultsch B; Horn J; Mikolajczyk RT; Greiner W; Wichmann O
    BMC Public Health; 2015 Jun; 15():533. PubMed ID: 26041469
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Rothberg MB; Virapongse A; Smith KJ
    Clin Infect Dis; 2007 May; 44(10):1280-8. PubMed ID: 17443464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review.
    Kawai K; Preaud E; Baron-Papillon F; Largeron N; Acosta CJ
    Vaccine; 2014 Mar; 32(15):1645-53. PubMed ID: 24534737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness Analysis of Herpes Zoster Vaccination in 50- to 85-Year-Old Immunocompetent Belgian Cohorts: A Comparison between No Vaccination, the Adjuvanted Subunit Vaccine, and Live-Attenuated Vaccine.
    Pieters Z; Ogunjimi B; Beutels P; Bilcke J
    Pharmacoeconomics; 2022 Apr; 40(4):461-476. PubMed ID: 35094374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
    Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
    Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium.
    Bilcke J; Marais C; Ogunjimi B; Willem L; Hens N; Beutels P
    Vaccine; 2012 Jan; 30(3):675-84. PubMed ID: 22120193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old.
    Van Oorschot D; Anastassopoulou A; Poulsen Nautrup B; Varghese L; von Krempelhuber A; Neine M; Lorenc S; Curran D
    Hum Vaccin Immunother; 2019; 15(1):34-44. PubMed ID: 30130448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Herpes zoster vaccine: A health economic evaluation for Switzerland.
    Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
    Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of the Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.
    Le P; Rothberg MB
    JAMA Intern Med; 2018 Feb; 178(2):248-258. PubMed ID: 29297049
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live.
    Curran D; Patterson BJ; Van Oorschot D; Buck PO; Carrico J; Hicks KA; Lee B; Yawn BP
    Hum Vaccin Immunother; 2019; 15(4):765-771. PubMed ID: 30625011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
    Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
    Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimal gender-specific age for cost-effective vaccination with adjuvanted herpes zoster subunit vaccine in Chinese adults.
    You JHS; Ming WK; Tsang OT; Chan PK
    PLoS One; 2019; 14(1):e0210005. PubMed ID: 30608953
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential impact of increased recombinant zoster vaccine coverage on the burden of herpes zoster among adults aged 50-59 years.
    Singer D; Salem A; Stempniewicz N; Ma S; Poston S; Curran D
    Vaccine; 2023 Aug; 41(37):5360-5367. PubMed ID: 37541822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany.
    Curran D; Van Oorschot D; Varghese L; Oostvogels L; Mrkvan T; Colindres R; von Krempelhuber A; Anastassopoulou A
    Hum Vaccin Immunother; 2017 Oct; 13(10):2213-2221. PubMed ID: 28708959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and economic impact of herpes zoster vaccination in elderly in Italy.
    Boccalini S; Alicino C; Martinelli D; Bechini A; Tiscione E; Pellizzari B; Prato R; Icardi G; Iannazzo S; Bonanni P
    Hum Vaccin Immunother; 2017 Feb; 13(2):405-411. PubMed ID: 27925856
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.